No retraction, correction or concern found when last checked on Oct 17, 2026.
The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota
PA Engen
Alcohol Research: Current Reviews · 2015 · Review
Abstract
The excessive use of alcohol is a global problem causing many adverse pathological health effects and a significant financial health care burden. This review addresses the effect of alcohol consumption on the microbiota in the gastrointestinal tract (GIT). Although data are limited in humans, studies highlight the importance of changes in the intestinal microbiota in alcohol-related disorders. Alcohol-induced changes in the GIT microbiota composition and metabolic function may contribute to the well-established link between alcohol-induced oxidative stress, intestinal hyperpermeability to luminal bacterial products, and the subsequent development of alcoholic liver disease (ALD), as well as other diseases. In addition, clinical and preclinical data suggest that alcohol-related disorders are associated with quantitative and qualitative dysbiotic changes in the intestinal microbiota and may be associated with increased GIT inflammation, intestinal hyperpermeability resulting in endotoxemia, systemic inflammation, and tissue damage/organ pathologies including ALD. Thus, gut-directed interventions, such as probiotic and synbiotic modulation of the intestinal microbiota, should be considered and evaluated for prevention and treatment of alcohol-associated pathologies.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.
It has been estimated that approximately 2 billion people worldwide drink alcohol on a daily basis, with more than 70 million people having a diagnosed alcohol use disorder. Globally, alcohol use is the fifth leading risk factor for premature death and disability among people between the ages of 15 and 49. Excessive alcohol consumption in the United States accounts for 80,000 deaths yearly and is the third leading preventable cause of death in the United States. In addition, the Centers for Disease Control and Prevention (CDC) found that in 2006, excessive drinking cost the United States more than $224 billion. In a subgroup of alcoholics, alcohol consumption is linked with tissue injury and organ dysfunction, including alcoholic liver disease (ALD), increased risk of developing cancer, abnormal function of the immune system that increases the risk of acute and chronic infections, pancreatitis, heart disease, and disruption of the circadian clock. The observation that only some alcoholics develop alcohol-induced pathology indicates that, although alcohol is necessary, it is not sufficient to cause organ dysfunction. Consequently, factors other than the toxicity of alcohol are involved in generating health complications, one of which may be alcohol-induced changes in intestinal microbiota composition and/or function.
The intestinal microbiota is classified as the total collection of microbial organisms (bacteria and microbes) within the gastrointestinal tract (GIT). It contains tens of trillions of microorganisms, including at least 1,000 different species of known bacteria, the vast majority of which belong to the phyla Firmicutes and Bacteroidetes. The metagenome is the collection of all the different genes found within the gut microbiome; the GIT microbiome contains more than 3 million unique genes, outnumbering the number of human genes 150 to 1. The GIT and the intestinal microbiota display a symbiotic relationship. The microbiota contributes to the extraction of energy from food and synthesis of vitamins and amino acids, and helps form barriers against pathogens. Disruption of intestinal microbiota homeostasis—called dysbiosis—has been associated with inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, food allergies, type 1 diabetes, type 2 diabetes, cancer, obesity, and cardiovascular disease. Although it is unclear whether dysbiosis is the cause or the result of these diseases, factors that contribute to the development and progression of many of these diseases are known to influence the GIT microbiota.
Dysbiosis can be caused by environmental factors commonly encountered in Western societies, including diet, disruption of circadian rhythms, and alcoholic beverage consumption (figure 1). It is well-established that diet influences intestinal microbiota composition and diversity (figure 1). Diets high in fat alter intestinal microbiota, as do “Western” diets, comprising high fat and high sugar. The consequence of diets high in fat or sugar may contribute to the development of obesity and liver injury, as well as IBD, IBS, celiac disease, type 1 and type 2 diabetes, food allergies, and cardiovascular disease, at least in genetically susceptible individuals. Alcohol is another dietary disruptor of the intestinal microbiota. A limited number of studies have examined the effects of alcohol on the microbiota in rodents and humans. These changes seem to be relevant for alcohol-associated pathologies because interventions known to alter the intestinal microbiota diminish some alcohol-associated pathologies such as liver disease.
In this review, we examine alcohol-induced effects on microbiota and how interventions targeted at normalizing alcohol-induced dysbiosis may mitigate some of the detrimental effects of alcohol.
Analyzing the Intestinal Microbial Community
Before we can understand the influence of alcohol on the GIT microbiota, we need to understand a bit about how researchers measure these microorganisms and evaluate changes in their populations. In fact, it is difficult to directly measure microbial communities such as those within the GIT because of a number of confounding factors. For one, microorganisms maintain incredible genetic diversity but house this diversity in an extraordinarily limited array of cellular morphologies. In addition, microorganisms have redundant functional capabilities, share divergent functional capabilities with closely related microorganisms, have the potential for high metabolic diversity within single microbial lineages, and are extraordinarily difficult to isolate under laboratory conditions. Taken together, these confounding factors compel researchers to use molecular tools—tools that examine DNA and RNA—to analyze these complex communities. These tools fall into two broad categories: polymerase chain reaction (PCR)–based targeted approaches and shotgun sequencing approaches (figure 2), which we explain in detail in the sidebar.
Because it is exceedingly difficult to obtain microbial samples from different locations in the GIT, researchers overwhelmingly extract the genomic DNA they need to analyze the GIT microbiota from mucosa-associated colonic tissue biopsies and from fecal samples. However, using these samples assumes that the colonic tissue and feces are a suitable proxy for the GIT. A study addressed this issue in an analysis of microbiota community structure in mouth, stomach, duodenum, colon, and stool, via gastroscopy and colonoscopy from four healthy individuals. When examined in the context of the entire GIT, colonic tissue and fecal samples were most similar to each other in all individuals. However, the community composition was substantially altered in colon and fecal samples from the same individual: three of four individuals had a much reduced level of microorganisms from the phylum Bacteroidetes in fecal samples. This led to a substantially altered ratio of Firmicutes to Bacteroidetes, a ratio that has been used as a diagnostic parameter in studies of disease (see sidebar). also found a similar divergence between GIT colonic tissue and fecal microbiota. Thus, although colonic tissue and fecal samples will continue to serve as common, imperfect proxies for GIT microbiota, they should not be considered a perfect representation of the entire GIT microbial community, which undergoes dramatic changes from the stomach to colon. No obvious solution is available, leaving only highly invasive sampling techniques as a mechanism to collect samples from multiple locations of the GIT.
Alcohol-Induced Effects and Implications on the Intestinal Microbiota
The study of alcohol’s effects on the structure and activity of GIT microbiota still is in its infancy, particularly compared with other alcohol-induced effects. The literature reviewed below demonstrates that alcohol consumption leads to quantitative and qualitative dysbiosis in the intestinal microbiota of rodents and humans (table 1). These studies demonstrate alterations in the dominant bacterial taxa from the phyla Bacteroidetes and Firmicutes and, in several studies, an increase in bacteria from the phylum Proteobacteria.
Rodent Models
Studies in mice and rats find both alcohol-induced bacterial overgrowth and dysbiosis. In one study, C57BL/6 mice were intragastrically fed alcohol (30.9 g/kg per day; 40 percent of their total daily calories from alcohol) for 3 weeks and compared with control mice intragastrically fed an isocaloric liquid diet. The alcohol-fed mice developed ALD, which was associated with small intestinal bacterial overgrowth and dysbiosis in the cecum—the beginning of the large intestine. In particular, the GIT microbiota of alcohol-treated mice showed a decrease in Firmicutes and an increase in the relative abundance of Bacteroidetes and Verrucomicrobia, among other bacteria (table 1). In comparison, the GIT microbiota of control-fed mice showed a relative predominance of bacteria from the phylum Firmicutes. In a separate study, Sprague-Dawley rats intragastrically fed alcohol daily (8 g/kg per day) for 10 weeks showed altered colonic mucosa–associated bacterial microbiota composition leading to ileal and colonic dysbiosis. In prior studies, Sprague-Dawley rats developed intestinal oxidative stress, intestinal hyperpermeability, endotoxemia, and steatohepatitis by the 10th week of alcohol treatment, suggesting that changes in the microbiota may be contributing to the alcohol-induced effects on the intestine and liver. Intestinal dysbiosis may potentially contribute to the pathogenesis of liver disease by altering intestinal barrier integrity, resulting in intestinal hyperpermeability, as well as increased production of proinflammatory factors that could both promote liver pathology.
Humans
Chronic alcohol consumption in humans also causes bacterial overgrowth and dysbiosis. One study using culture-based methods, for example, found alcohol-induced alterations, including small intestine bacterial overgrowth of both aerobic and anaerobic bacteria in the jejunum. Another study showed that alcohol consumption alters the composition of mucosa-associated microbiota in human sigmoid biopsies taken from alcoholics with and without ALD as well as healthy control subjects. In this study, the researchers used 16S rRNA gene sequencing to assess the microbiota. They found that the microbial community was significantly altered—containing a lower abundance of Bacteroidetes and a higher abundance of Proteobacteria—in a subgroup of alcoholics with and without liver disease (table 1). Other studies show that dysbiotic microbiota in alcoholics also correlates with a high level of endotoxin in the blood, indicating that dysbiosis may contribute to intestinal hyperpermeability and/or the increased translocation of gram-negative microbial bacterial products from the intestinal lumen into systemic circulation. Similarly, 16S rRNA gene analysis of fecal microbiota from human subjects with hepatitis B or alcohol-related cirrhosis shows a reduction in Bacteroidetes and an increase in Proteobacteria and Fusobacteria, compared with healthy control subjects (table 1). At a finer taxonomic resolution, this study also shows a significant increase in potentially dangerous bacteria from the families Prevotellaceae, Enterobacteriaceae, Veillonellaceae, and Streptococcaceae in subjects with alcoholic cirrhosis, compared with subjects with hepatitis B cirrhosis and with control subjects. The prevalence of potentially pathogenic bacteria in patients with cirrhosis may affect prognosis, something supported by previous research. Other lower resolution studies find that the relative abundance of bacteria from the phylum Bacteroidetes decreases as those from the phylum Proteobacteria increase and that individuals with cirrhosis exhibit a unique increase in Fusobacteria. Overall, alcoholics and cirrhosis patients demonstrate microbial communities enriched in Proteobacteria of the class Gammaproteobacteria and Firmicute of the class Bacilli. In contrast, Firmicutes of the class Clostridia are depleted in alcoholics but are not significantly changed in the cirrhosis group, with the exception of Veillonellaceae, which is increased and Lachnospira, which is decreased (table 1). These findings suggest that microbiota community differences between alcoholics and alcoholics with cirrhosis (e.g., Fusobacteria, Clostridia) may contribute to the development of liver disease or may be a biomarker indicating liver disease (figure 3). Future studies will need to determine the cause-and-effect relationship of the microbiota community structure and liver disease.
To understand the results of microbiota analyses, it can help to understand a bit about the methods researchers use. As mentioned in the main article, researchers tend to use techniques that look for DNA and RNA related to specific microorganisms. To do that, they typically use one of two techniques: polymerase chain reaction (PCR) and shotgun sequencing. Here, we explain in general terms how each method is used to analyze GIT microbiota.
PCR
To successfully use PCR, researchers needed to find an appropriate gene target that would be common enough among microorganisms so they could use a known segment for searching but different enough so that they could individuate among microorganisms. They quickly selected ribosomal RNA (rRNA) genes. Ribosomal RNAs are essential for protein synthesis within all cells and therefore their genes have many features that make them desirable for determining the makeup of complex microbial communities. In particular, the genes contain regions of DNA that are highly variable among species and so can serve as a kind of identifier; but they also contain regions that are highly conserved, or the same among many species, and are therefore suitable for the development of broad-range PCR primers that use snippets of known DNA to search for specific genes. As a result of these features, rRNA genes have become the “gold standard” for molecular analyses, and they are typically analyzed using PCR-based techniques coupled with indirect fingerprinting or direct sequencing, including with next-generation sequencing (NGS). To profile GIT microbial communities using rRNA gene analysis, researchers typically extract genomic DNA from mucosa-associated colonic biopsies and fecal matter. They then use PCR to amplify the DNA, creating what are called “amplicons,” using primers targeting conserved regions of the small subunit (SSU or 16S) rRNA gene from all bacteria and sometimes archaea. The researchers then sequence these PCR amplicons after suitable preparation for the chosen sequencing platform. Whereas it was previously common to have clone libraries on the order of 100 sequences per sample, it is more typical with NGS approaches to have sequence libraries of 10,000 to 100,000 sequences per sample. A suite of bioinformatics tools has been developed to process this high-throughput data such as RDP, mothur, and QIIME.
Because of limitations inherent in the analysis of a structural gene, such as the rRNA gene that is common to all organisms, this method should be viewed as the first step in a multi-tiered approach to the analysis of microbial communities. The following are some limitations: (1) rRNA gene sequencing does not provide definitive physiological information about an organism; (2) for DNA-based methods, the presence of an organism’s rRNA gene does not guarantee that the organism is active in the studied system at the time of sampling; (3) variation in the number of rRNA genes among bacterial lineages distorts the true diversity of microorganisms in an environmental sample; and (4) difficulty in species- and strain-level phylogenetic resolution among some taxa, depending upon the region of rRNA gene analyzed. Nonetheless, for large studies with many samples, a preliminary screen using this method is often suitable for identifying large-scale shifts in microbial community structure and for identifying statistically significant changes in the relative abundance of organisms between groups or treatments.
That said, the interpretation of results from the analysis of microbial community composition using DNA-based methods can be confounded by the presence of DNA from dead, dormant, or weakly active organisms contributing little to overall microbial community function. To circumvent these limitations, researchers can directly target rRNAs instead of rRNA genes. In such an approach, researchers extract total RNA from an environmental sample and reverse transcribe this RNA using either a random primer mix or a gene-specific “reverse” primer matching the rRNA (figure 2). This process generates single-stranded complementary DNA (cDNA), which is then used as a template for PCR and sequencing with domain-level primer sets as is done with genomic DNA. As microbial RNA is labile and degrades rapidly if not continually produced, rRNA analysis reflects only active microorganisms, and the relative abundance of rRNAs represents the relative activity of organisms in the system. Although rRNA analysis still does not provide an explicit link to physiology for most organisms, such analyses may find stronger correlation to measured functions at the time of sampling. Microbial RNA degrades rapidly, and for GIT colonic tissue and fecal samples, the time delay until RNA can be extracted may result in a serious distortion of active organisms and gene expression patterns from in situ. Thus, animal model systems in which animals are killed for sampling may be more suitable for RNA studies as mRNAs and ribosomes can be preserved rapidly for downstream analyses.
Shotgun Metagenomic and Metatranscriptomic Sequencing
Although amplicon sequencing approaches are extremely useful for GIT microbiota community characterization, they are limited by the need to have some known DNA sequences to look for. Therefore, to detect novel genes and gene variants, it is necessary to have sequencing approaches that do not depend on such information. Researchers use so-called “shotgun” sequencing approaches (figure 2) to circumvent the need for a priori sequence information through the use of molecular manipulations of nucleic acids to attach known sequences for priming of sequencing reactions to unknown sequences. Shotgun sequencing approaches, in which no a priori selection of a region or gene of interest is performed, provides a holistic view of microbial communities, gene content, and expression patterns. However, low-abundance taxa or those with small genomes, like viruses, may be swamped out by high-abundance or large genome organisms and may benefit from targeted amplification approaches.
Two techniques are used for more detailed assessments of GIT microbiota functional capabilities: In shotgun metagenomics, total genomic DNA is fragmented and sequenced directly, and in shotgun metatranscriptomics, fragmented messenger RNAs are sequenced directly. These techniques can provide data to identify active organisms and metabolic activities at the time of sampling (metatranscriptome) and to directly link community function to specific microbial lineages, even at the species or subspecies level (metagenome and metatranscriptome). Such in-depth analyses can identify key GIT microbiota community members, identify essential genes associated with the GIT microbiota, and improve metabolic modeling to predict the physiology of dominant organisms in environments undergoing global changes. Metagenome sequencing can provide much more detailed taxonomy of communities based on genes other than rRNAs, particularly at the species and strain level. In particular, GIT microbiota analyses of disease states and obesity have found widespread application. A full survey of the methods for analysis of metagenomic data is beyond this review; however, many recent articles provide deeper overviews and describe suitable pipelines.
Although powerful, these approaches are limited by many factors:
High cost attributed to heavy sequence demand;
Insufficiently robust reference databases to provide suitable annotation to all recovered gene fragments;
High microbial diversity in the GIT, which leads to limited coverage of most organisms aside from highly abundant organisms;
High transcript abundance of housekeeping genes; and
High computer memory and computational demand for analysis.
Because of the relatively high cost of shotgun sequencing approaches relative to amplicon sequencing approaches (typically about 20 to 30 times higher cost), researchers must carefully tailor their project goals to the appropriate molecular methodology. In a tiered sequencing approach, researchers perform amplicon sequencing on all samples and use their analysis of amplicon data to select critical or representative samples for deeper sequence analysis.
Considerations for Nucleic Acid Extraction
Analysis of gastrointestinal tract (GIT) microbiota communities presents several features worthy of consideration. In particular, researchers take the majority of samples from feces and mucosa-associated colonic tissue biopsies. Traditionally, extraction of nucleic acids from mammalian feces generated nucleic acid templates of poor purity. However, new extraction protocols and commercial kits have largely removed nucleic acid purity as a limitation to downstream molecular analyses. Indeed, many manufacturers produce kits specifically for GIT colonic tissue and fecal DNA extraction (e.g., Mo Bio PowerFecal® DNA Isolation Kit; Qiagen QIAamp DNA Stool Mini Kit; Zymo ZR Fecal DNA MiniPrep kit; Epicentre ExtractMaster™ Fecal DNA Extraction Kit). Although many of these extraction kits have similar chemistry, other features of the kits may be critical to the maximum recovery of genomic DNA from GIT colonic tissue and feces and to minimize distortion of the GIT microbiota community as a result of differential lysis of different types of microbial cells.
Mammalian GIT microbiota communities are dominated by bacteria from two phyla: Bacteroidetes and Firmicutes, and researchers have used the ratio of these phyla as a diagnostic parameter. For example, observed dramatic age-related changes in the ratio of Firmicutes and Bacteroidetes (F/B) in feces from healthy individuals, and the ratio has been broadly utilized in studies of obesity, with greater numbers of Firmicutes in obese patients. That said, sampling processing procedures can affect this ratio because the phylum Firmicutes consists of mostly gram-positive bacteria with thick cell walls that can make them difficult to lyse, thus high-energy lysis steps (e.g., bead-beating) are important in extraction protocols. In addition, lytic enzymes such as lysozyme, mutanolysin, and lysostaphin can be used individually or in combination to enhance lysis of difficult-to-lyse organisms. One study demonstrated that freezing of fecal samples prior to DNA extraction can alter the F/B ratio, with enhanced relative abundance of Firmicutes after freezing. As a result of these issues, it may be difficult to easily compare directly between studies of fecal samples processed under different conditions. Likewise, protocols should be carefully considered and rigorously adhered to in order to provide reproducible handling for each sample.
Humans
Although alcohol can cause intestinal dysbiosis, some alcoholic beverages contain compounds that may favorably alter the GIT microbiota community composition. A study showed the effects of dietary polyphenols on the human GIT microbiota in human healthy control subjects who consumed red wine (272 mL per day), de-alcoholized red wine (272 mL per day), or gin (100 mL per day) for 20 days and had their total fecal DNA assessed from stool collected at baseline and after treatment. Red wine polyphenol significantly increases the abundance of Proteobacteria, Fusobacteria, Firmicutes and Bacteroidetes, whereas gin consumption significantly decreases these same bacterial phyla (table 1). De-alcoholized red wine consumption significantly increases Fusobacteria, and gin consumption increases Clostridium abundance compared with de-alcoholized and red wine (table 1). Red wine and de-alcoholized red wine consumption increases the abundance of Bifidobacterium, a bacterium that has been shown to be beneficial in the GIT. Thus, it seems that polyphenol consumption is associated with an increase in bacteria that are known to promote GIT health, whereas alcohol consumption alone may be damaging to the microbiota balance. The significant decrease of Clostridium associated with the consumption of red wine polyphenols suggests that polyphenols may have an inhibitory effect on the growth of Clostridium, which has been linked to the progression of colonic cancer and the onset of IBD. These results indicate that polyphenol consumption may be used as a dietary intervention to alter the microbiota in a specific way. In addition, daily moderate consumption of red wine polyphenols increases the growth of Bifidobacterium, which could be associated with positive prebiotic effects of GIT microbiota, production of beneficial organic acids, and the growth inhibition of pathogenic bacteria. Also, as an important consideration to evaluating alcohol-induced effects on the GIT microbiota, differences attributed to the type of alcohol consumption may be contributing to intra- and interstudy variability.
Whether alcohol-induced dysbiosis contributes to the pathogenesis of diseases, such as ALD or alcohol-related cirrhosis, is undetermined. Future studies will need to determine the biological, functional, and clinical significance of the dysbiotic intestinal microbiota composition in alcohol-related disorders.
From Dysbiosis to Disease
Once alcohol disrupts the intestinal microbiota, both the microbiota and microbiome may increase susceptibility to pathological changes. The majority of the reviewed studies indicate an association between alcohol-induced intestinal bacterial overgrowth and dysbiosis and the development/progression of ALD and cirrhosis. Indeed, disrupted intestinal barrier function, which is associated with alcohol consumption, in combination with alcohol-induced bacterial overgrowth and dysbiosis, could be highly relevant for the development of alcohol-induced liver pathology, including nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and ALD. Studies show that alcohol consumption disrupts the intestinal barrier via increasing oxidative stress burden in the intestine, which in turn disrupts tight junctions and promotes intestinal hyperpermeability. Increased intestinal hyperpermeability allows proinflammatory/pathogenic microbial products, including endotoxin (e.g., lipopolysaccharide [LPS] and peptidoglycan), to translocate from the intestinal lumen to the liver via the portal vein. Exposure to these bacterial products causes inflammation in the liver, which may work in conjunction with the direct effects of alcohol to cause ALD. This translocation of viable bacterial products during bacterial overgrowth or alcohol-induced dysbiosis may significantly contribute to end-stage liver disease observed in alcohol cirrhosis patients and may therefore contribute to the mortality of cirrhotic patients by inducing infection.
Interventions to Normalize Alcohol-Induced Intestinal Dysbiosis
Research in rodents and humans has begun to investigate whether alcohol-induced intestinal dysbiosis and its consequences may be reversible with probiotic and synbiotic interventions (table 2). Probiotics are live microorganisms that, when taken by the host, have beneficial effects on the host beyond their simple nutritive value. Synbiotics are a combination of probiotics and prebiotics—nondigestible fibrous compounds, such as oats, that stimulate the growth and activity of advantageous bacteria in the large intestine.
Probiotics, especially Lactobacillus rhamnosus GG (LGG), have several beneficial effects on intestinal function, including stimulating intestinal development and mucosal immunity, ameliorating diarrhea, prolonging remission in ulcerative colitis and pouchitits, reducing intestinal oxidative stress, and maintaining or improving intestinal barrier function. Synbiotics have been demonstrated to favorably alter liver metabolism in alcohol-fed animals.
Studies in rodents demonstrate that both probiotics and prebiotics prevent alcohol-induced dysbiosis. A study in Sprague-Dawley rats that had consumed alcohol (8 g/kg per day) daily for 10 weeks showed that intragastrically feeding them probiotic LGG (2.5 × 107 live once daily) or prebiotic oats (10 g/kg) prevented alcohol-induced GIT dysbiosis. The rats given the interventions had microbiota composition profiles similar to that of control rats that were intragastrically fed an isocaloric dextrose diet for 10 weeks. This finding corresponds to results obtained in an ALD rodent model demonstrating that LGG attenuates endoxtemia and alcoholic steatohepatitis. Furthermore, LGG and oat supplementation ameliorates alcohol-induced intestinal oxidative stress, intestinal hyperpermeability, and liver injury in rodent models of alcohol steatohepatitis. In another study, researchers orally fed C57BL/6 mice the Lieber-DeCarli diet with or without alcohol (5% vol/vol) for 6 weeks and gave a subset of the mice 1 mL of LGG (bacterial density 1 × 109 cfu/mL) orally each day for 6 to 8 weeks. Similar to other findings, the alcohol-fed mice demonstrated a decrease in the abundance of Bacteriodetes and Firmicutes and an increase in Proteobacteria and Actinobacteria (table 2). However, probiotic LGG supplementation prevented this alcohol-induced dysbiotic intestinal microbiota composition, especially increasing Firmicutes, including Lactobacillus. Other studies find that LGG prevents alcohol-induced intestinal hyperpermeability, endotoxemia, and liver injury, supporting the notion that LGG may be a therapeutic approach to decrease the development of ALD.
Studies in humans show similar results. One study examined Minimal Hepatic Encephalopathy (MHE) patients with cirrhosis who typically have substantial alterations in their GIT microbiota composition caused by the overgrowth of the potentially pathogenic Escherichia coli and Staphylococcal species (table 2). Following 30 days of synbiotic and prebiotic treatments, these patients had significantly reduced viable counts of potentially pathogenic GIT microbiota with a concurrent significant increase in fecal content of Lactobacillus species (table 2). Half of the patients receiving synbiotic treatment also exhibited a significant reduction in blood ammonia levels, endotoxemia, and reversal of MHE, when compared with control subjects. These improvements in MHE correlate with similar findings showing that probiotic supplementation improved hepatic encephalopathy (HE) in patients with cirrhosis. Interestingly, probiotic LGG supplementation prevents alcohol-induced dysbiosis of the intestinal microbial community, and leads to an increase in Firmicutes, particularly of the genus Lactobacillus. Furthermore, in an U.S. Food and Drug Administration phase I study, the administration of probiotic LGG to cirrhotic patients with MHE (most of whom had Hepatitis C–induced cirrhosis) found that LGG significantly reduces dysbiosis, tumor necrosis factor (TNF)-α, and endotoxemia in comparison to placebo. In addition, LGG shows beneficial changes in the stool microbial profiles and significant changes in metabolite/microbiota correlations associated with amino acid, vitamin, and secondary bile-acid metabolism in comparison to MHE cirrhotic patients randomly assigned to placebo. In a comparison of the synbiotic and prebiotic treatment to cirrhotic patients with MHE in the study above, probiotic LGG does promote beneficial microbiota; however, it does not increase Lactobacillus and does not improve cognitive function in the patients for this randomized clinical trial. Thus, taken together, probiotics and/or synbiotics may be a viable approach in humans to alter the GIT microbiota to a more favorable profile to improve clinical outcomes (figure 3).
Therapeutic Intervention for Treating Alcohol-Induced Intestinal Dysbiosis
The therapeutic intervention studies in this review indicate that in ALD rodent models and MHE alcohol-cirrhosis humans, probiotic and synbiotic intervention increases Lactobacillus and Bifidobacterium (table 2). These findings suggest that the intestinal microbiota play a role in attenuating alcohol-induced dysbiosis and liver injury. In addition, the modulation of intestinal microbiota could be a viable therapeutic strategy to prevent or normalize alcohol-induced dysbiosis and which would be expected to have beneficial effects on alcohol-induced liver injury as well as other inflammatory-mediated diseases resulting from chronic alcohol consumption.
Dysbiosis is a term used to describe a microbial imbalance on or inside the body, commonly within the digestive tract where it has been associated with illness
The presence of endotoxins in the blood, where endoxins are toxic substances bound to the cell wall of certain bacteria
A biochemical technology used to amplify a single or a few copies of a particular piece of DNA, generating millions of copies of that DNA sequence. Among other uses, the technique allows researchers to make enough copies of a piece of DNA to sequence it. PCR requires “primers” or small snippets of DNA that match a piece of the DNA researchers are attempting to replicate
A type of cytokine, or cell-signaling protein that can cause cell death
Evidence suggests that probiotic and synbiotic interventions can not only reverse alcohol-induced dysbiosis but can improve the pathogenesis symptoms of the GIT and liver in ALD. Treatment with probiotics prevents or significantly decreases alcohol-induced intestinal permeability, intestinal oxidative stress and inflammation of the intestine and liver, TNF-α production, and expression of intestinal trefoil factor and its transcriptional regulator hypoxia-inducible factor-2α (HIF-2α) and attenuates endotoxemia and alcoholic steatophepatitis in rodent models and in humans with ALD. Probiotics also restore stool microbiota community structure and liver enzymes in ALD human patients. In addition, prebiotic oat supplementation prevents alcohol-induced gut leakiness in an ALD rat model by preventing alcohol-induced oxidative tissue damage. Thus, these studies suggest that probiotics (e.g., Lactobacillus) transform the intestinal microbiota community composition, which may prevent alcohol-induced dysbiosis, intestinal permeability, bacterial translocation, endotoxemia, and the development of ALD. Transformation of the intestinal microbiota may be a therapeutic target for the treatment of intestinal barrier dysfunction and the development of ALD.
Clinical studies suggest that probiotic consumption of Lactobacilli, Bifidobacteria, and Lactocooci are effective for the prevention and treatment of a diverse range of disorders. History shows that probiotic consumption is safe in healthy people but must still be taken with caution in certain patient groups, including premature neonates, people with immune deficiency, people with short-bowel syndrome, people with central venous catheters, the elderly, and people with cardiac disease. Clinical trials show that the effects of probiotics are variable depending on age, health, and disease state. Probiotic use also has its concerns. It presents a major risk of sepsis and has been associated with diseases such as bacteremia or endocarditis, toxic or metabolic effects on the GIT, and the transfer of antibiotic resistance in the gastrointestinal flora. In addition, the many properties of different probiotic species vary and can be strain specific. Therefore, the effect of new probiotic strains should be carefully analyzed in clinical trials before assuming they are safe to market as a potential therapeutic treatment.
Future Directions
Chronic alcohol consumption causes intestinal dysbiosis in both rodent models and humans. Dysbiosis in the intestinal microbiota may contribute to the pathogenesis of liver disease by altering intestinal barrier function leading, for example, to gut leakiness, the production of proinflammatory/pathogenic microbial products, and/or liver metabolic pathways. Further investigation into intestinal microbiota composition in alcoholism is necessary to identify new diagnostic as well as therapeutic targets to prevent alcohol-associated diseases, such as ALD. Such therapeutic avenues could include probiotics, prebiotics, synbiotics, or polyphenols to alleviate the symptoms associated with alcohol disorders. Thus, understanding the effect of alcohol on intestinal microbiota composition, may lead to a better understanding of its future functional activity, with the ultimate goal to restore intestinal microbiota homeostasis.
References 96
- 1.
Bahl MI, Bergstrom A, Licht TR. Freezing fecal samples prior to DNA extraction affects the Firmicutes to Bacteroidetes ratio determined by downstream quantitative PCR analysis. FEMS Microbiology Letters. 2012;329(2):193-197.
Not in our library10.1111/j.1574-6968.2012.02523.x
- 2.
Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nature Methods. 2010;7(5):335-336.
Not in our library10.1038/nmeth.f.303
- 3.
Cho I, Blaser MJ. The human microbiome: At the interface of health and disease. Nature Reviews Genetics. 2012;13(4):260-270.
Not in our library10.1038/nrg3182
- 4.
- 5.
Cole JR, Chai B, Farris RJ, et al. The Ribosomal Database Project (RDP-II): Sequences and tools for high-throughput rRNA analysis. Nucleic Acids Research. 2005;33:D294-D296.
Not in our library10.1093/nar/gki038
- 6.
Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(2):594-599.
Not in our library10.1073/pnas.1116053109
- 7.
Huson DH, Auch AF, Qi J, Schuster SC. MEGAN analysis of metagenomic data. Genome Research. 2007;17(3):377-386.
Not in our library10.1101/gr.5969107
- 8.
Karlsson FH, Fak F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature Communications. 2012;3:1245.
Not in our library10.1038/ncomms2266
- 9.
Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103.
Not in our library10.1038/nature12198
- 10.
Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nature Biotechnology. 2013;31(9):814-821.
Not in our library10.1038/nbt.2676
- 11.
Ley RE, Hamady M, Lozupone C, et al. Evolution of mammals and their gut microbes. Science. 2008;320(5883):1647-1651.
Not in our library10.1126/science.1155725
- 12.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
Not in our library10.1038/4441022a
- 13.
Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55(2):205-211.
Not in our library10.1136/gut.2005.073817
- 14.
- 15.
- 16.
Morowitz MJ, Denef VJ, Costello EK, et al. Strain-resolved community genomic analysis of gut microbial colonization in a premature infant. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(3):1128-1133.
Not in our library10.1073/pnas.1010992108
- 17.
Ó Cuív P, Aguirre de Carcer D, Jones M, et al. The effects from DNA extraction methods on the evaluation of microbial diversity associated with human colonic tissue. Microbial Ecology. 2011;61(2):353-362.
Not in our library10.1007/s00248-010-9771-x
- 18.
Pace NA, Stahl DA, Lane DJ, Olsen GJ. The analysis of natural microbial populations by ribosomal RNA sequences. Advances in Microbial Ecology. 1986;9:1-55.
Not in our library
- 19.
Perez-Cobas AE, Gosalbes MJ, Friedrichs A, et al. Gut microbiota disturbance during antibiotic therapy: A multi-omic approach. Gut. 2013;62(11):1591-1601.
Not in our library10.1136/gutjnl-2012-303184
- 20.
- 21.
Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60.
Not in our library10.1038/nature11450
- 22.
Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.
Not in our library10.1038/nature08821
- 23.
Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Applied and Environmental Microbiology. 2009;75(23):7537-7341.
Not in our library10.1128/aem.01541-09
- 24.
- 25.
Woese CR. Bacterial evolution. Microbiology Reviews. 1987;51(2):221-271.
Not in our library10.1128/mr.51.2.221-271.1987
- 26.
- 27.
Zakrzewski M, Bekel T, Ander C, et al. MetaSAMS: A novel software platform for taxonomic classification, functional annotation and comparative analysis of metagenome datasets. Journal of Biotechnology. 2013;167(2):156-165.
Not in our library10.1016/j.jbiotec.2012.09.013
- 28.
Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology & Therapeutics. 2014;39(10):1113-1125.
Not in our library10.1111/apt.12695
- 29.
Bode JC, Bode C, Heidelbach R, et al. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology. 1984;31(1):30-34.
Not in our library
- 30.
Bouchery EE, Harwood HJ, Sacks JJ, et al. Economic costs of excessive alcohol consumption in the U.S., 2006. American Journal of Preventive Medicine. 2011;41(5):516-524.
Not in our library10.1016/j.amepre.2011.06.045
- 31.
Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: What are the risks? American Journal of Clinical Nutrition. 2006;83(6):1256-1264.
Not in our library10.1093/ajcn/83.6.1256
- 32.
- 33.
Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Alimentary Pharmacology & Therapeutics. 2004;20(7):813-819.
Not in our library10.1111/j.1365-2036.2004.02174.x
- 34.
- 35.
Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772.
Not in our library10.2337/db06-1491
- 36.
Alcohol-attributable deaths and years of potential life lost: United States, 2001. MMWR Morbidity and Mortality Weekly Report. 2004;53(37):866-870.
Not in our library
- 37.
Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562-572.
Not in our library10.1002/hep.24423
- 38.
Chowdhury P, Gupta P. Pathophysiology of alcoholic pancreatitis: An overview. World Journal of Gastroenterology. 2006;12(46):7421-7427.
Not in our library10.3748/wjg.v12.i46.7421
- 39.
David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-563.
Not in our library10.1038/nature12820
- 40.
Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635-1638.
Not in our library10.1126/science.1110591
Cited by papers we hold 12
- An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites · 2021No notice
- Pulmonary immune cell trafficking promotes host defense against alcohol-associated Klebsiella pneumonia · 2021Not checked
- Expresión de alfa sinucleína en sangre y su relación con el estreñimiento crónico en población residente en Bogotá, D.C., con problemas de consumo de alcohol · 2020Not checked
- Intestinal microbiology shapes population health impacts of diet and lifestyle risk exposures in Torres Strait Islander communities · 2020Not checked
- Alcohol or Gut Microbiota: Who Is the Guilty? · 2019No notice
- Diet in Parkinson's Disease: Critical Role for the Microbiome · 2019No notice
- Colorectal Cancer and Alcohol Consumption—Populations to Molecules · 2018Corrected
- Gut-Brain Psychology: Rethinking Psychology From the Microbiota–Gut–Brain Axis · 2018No notice
- Alcoholic Liver Disease: Alcohol Metabolism, Cascade of Molecular Mechanisms, Cellular Targets, and Clinical Aspects · 2018No notice
- Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer · 2017No notice
- A Critical Review on Health Promoting Benefits of Edible Mushrooms through Gut Microbiota · 2017No notice
- Alcohol and Gut-Derived Inflammation · 2017No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.